Nonsteroidal anti-inflammatory drugs (NSAIDs) are a drug class FDA-approved for use as antipyretic, anti-inflammatory, and analgesic agents. These effects make NSAIDs useful for the treatment of muscle pain, dysmenorrhea, arthritic conditions, pyrexia, gout, migraines, and used as opioid-sparing agents in certain acute trauma cases.
NSAIDs are typically divided into groups based on their chemical structure and selectivity: acetylated salicylates (aspirin), non-acetylated salicylates (diflunisal, salsalate), propionic acids (naproxen, ibuprofen, acetic acids (diclofenac, indomethacin), enolic acids (meloxicam, piroxicam) anthranilic acids (meclofenamate, mefenamic acid), naphthylalanine (nabumetone), and selective COX-2 inhibitors (celecoxib, etoricoxib).
Listed below are the FDA-approved NSAIDs (organized alphabetically):
COX-2 Selective NSAIDs
(However, rofecoxib and valdecoxib were withdrawn from the market in 2004 and 2005, respectively)
The main mechanism of action of NSAIDs is the inhibition of the enzyme cyclooxygenase (COX). Cyclooxygenase is required to convert arachidonic acid into thromboxanes, prostaglandins, and prostacyclins. The therapeutic effects of NSAIDs are attributed to the lack of these eicosanoids. Specifically, thromboxanes play a role in platelet adhesion, prostaglandins cause vasodilation, increase the temperature set-point in the hypothalamus, and play a role in anti-nociception.
There are two cyclooxygenase isoenzymes, COX-1 and COX-2. COX-1 gets constitutively expressed in the body, and it plays a role in maintaining gastrointestinal mucosa lining, kidney function, and platelet aggregation. COX-2 is not constitutively expressed in the body, and instead it inducibly expresses during an inflammatory response. Most of the NSAIDs are nonselective and inhibit both COX-1 and COX-2. However, COX-2 selective NSAIDs (ex. celecoxib) only target COX-2 and therefore have a different side effect profile. Importantly, because COX-1 is the prime mediator for ensuring gastric mucosal integrity and COX-2 is mainly involved in inflammation, COX-2 selective NSAIDs should provide anti-inflammatory relief without compromising the gastric mucosa.
Most commonly, NSAIDs are available as oral tablets. According to the package insert, the dosage for the most common over-the-counter NSAIDs are as follows:
Topical NSAIDs are also available (diclofenac sodium 1.5% topical solution, diclofenac hydroxyethyl pyrrolidine 1.3% patch, and diclofenac sodium gel 1%). They are most useful for treating pain due to soft-tissue injuries and osteoarthritis.
Specific NSAIDs can also be administered parenterally, for example, intravenous ibuprofen is available, given as a 30-minute infusion; this can be used as a non-opioid analgesic to manage pain and can also reduce fever. Trials have shown that using intravenous ibuprofen along with morphine in postoperative adult patients has the potential to lower the total use of morphine. For treating pyrexia an initial 400mg dose then 400 or 100 to 200 mg every 4 to 6 hours as needed. For the treatment of pain, 400 to 800 mg, every 6 hours as needed is the recommendation. Ketorolac is also available for parenteral administration.
NSAIDs have well-known adverse effects affecting the gastric mucosa, renal system, cardiovascular system, hepatic system, and hematologic system.
Gastric adverse effects are likely due to the inhibition of COX-1, preventing the creation of prostaglandins that protect the gastric mucosa. The damage is more likely in a patient that has a prior history of peptic ulcers. Since it is COX-1 specific, the use of COX-2 selective NSAIDs is a lower risk alternative.
Renal adverse effects are because COX-1 and COX-2 facilitate the production of prostaglandins that play a role in renal hemodynamics. In a patient with normal renal function, inhibition of prostaglandin synthesis does not pose a large problem; however, in a patient with renal dysfunction, these prostaglandins play a greater role and can be the source of problems when reduced via NSAIDs. Complications that can occur due to this are acute renal dysfunction, fluid and electrolyte disorders, renal papillary necrosis, and nephrotic syndrome/ interstitial nephritis.
Cardiovascular adverse effects can also be increased with NSAID use; these include MI, thromboembolic events, and atrial fibrillation. Diclofenac seems to be the NSAID with the highest reported increase in adverse cardiovascular events.
Hepatic adverse effects are less common; NSAID-associated risk of hepatotoxicity (raised aminotransferase levels) is not very common, and liver-related hospitalization is very rare. Among the various NSAIDs, Diclofenac has a higher rate of hepatotoxic effects.
Hematologic adverse effects are possible, particularly with nonselective NSAIDs due to their antiplatelet activity. This antiplatelet effect typically only poses a problem if the patient has a history of GI ulcers, diseases that impair platelet activity (hemophilia, thrombocytopenia, von Willebrand, etc.), and in some perioperative cases.
For a complete list of adverse effects for an individual NSAID, please see the StatPearls article for that particular drug.
According to the package insert NSAIDs are contraindicated in patients:
Recommended monitoring includes a CBC, renal tests, and hepatic panel. These recommendations are from the American College of Rheumatology for use in rheumatoid arthritis patients who use NSAIDs chronically and who have no comorbidities nor history of complications. Monitoring is less common in patients not considered high risk for NSAID toxicity. However, NSAIDs are either contraindicated, or their use requires monitoring, in patients with liver or renal problems.
NSAID toxicity can manifest as GI bleeding, hypertension, hepatotoxicity, and renal damage.  Typically, acute NSAID overdose is asymptomatic or has negligible gastrointestinal symptoms. However, other symptoms of toxicity complications may include anion gap metabolic acidosis, coma, convulsions, and acute renal failure. Also, NSAIDs can confer gastrointestinal damage by inhibiting COX-1, which causes decrease gastric mucosa production. Nephrotoxicity can also occur with NSAID use because these medications reduce prostaglandin levels, which are essential for the vasodilation of the renal arterioles. Lastly, neurologic toxicity can present with drowsiness, confusion, nystagmus, blurred vision, diplopia, headache, and tinnitus.
The general public widely uses NSAIDs because of their wide range of commonly encountered indications. Patient education on the use of NSAIDs is an important piece of care that providers need to pay attention to because of the many possible adverse effects on multiple different organ systems. Because these adverse effects occur at a much higher rate in patients with specific comorbidities, it is crucial for physicians, nurses, and pharmacists to pay close attention to a patient's history and to educate the patient accordingly on risks and dosing. The treating clinician will initiate therapy, whether for a short or long-term regimen. The pharmacist will need to verify the dosing and administration, as well as checking for potential drug-drug interactions. Pharmacists should also offer patient counseling on how to best use their NSAID and minimize adverse events; this is particularly the case when the patient uses NSAIDs as an OTC agent. Nursing must also take a careful medication history, and include OTC NSAID use, so the clinician can make an informed choice for prescribing NSAID therapy. MUrses, pharmacists, and clinicians all need to be cognizant of the signs and symptoms of NSAID toxicity or adverse effects, so that changes can be made to the patient's regimen as needed.
The healthcare team should communicate and work together to ensure that each patient receives the proper dose for their specific condition and comorbidities; high enough for efficacy but as low as possible to reduce the incidence of adverse effects. Through collaborative interprofessional teamwork, NSAID therapy can confer maximum benefit with minimal downside. [Level 5]
|||Phillips WJ,Currier BL, Analgesic pharmacology: II. Specific analgesics. The Journal of the American Academy of Orthopaedic Surgeons. 2004 Jul-Aug; [PubMed PMID: 15473674]|
|||Dawood MY, Primary dysmenorrhea: advances in pathogenesis and management. Obstetrics and gynecology. 2006 Aug; [PubMed PMID: 16880317]|
|||Shekelle PG,Newberry SJ,FitzGerald JD,Motala A,O'Hanlon CE,Tariq A,Okunogbe A,Han D,Shanman R, Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline. Annals of internal medicine. 2017 Jan 3; [PubMed PMID: 27802478]|
|||Oyler DR,Parli SE,Bernard AC,Chang PK,Procter LD,Harned ME, Nonopioid management of acute pain associated with trauma: Focus on pharmacologic options. The journal of trauma and acute care surgery. 2015 Sep; [PubMed PMID: 26307883]|
|||Zacher J,Altman R,Bellamy N,Brühlmann P,Da Silva J,Huskisson E,Taylor RS, Topical diclofenac and its role in pain and inflammation: an evidence-based review. Current medical research and opinion. 2008 Apr; [PubMed PMID: 18279583]|
|||van den Bekerom MPJ,Sjer A,Somford MP,Bulstra GH,Struijs PAA,Kerkhoffs GMMJ, Non-steroidal anti-inflammatory drugs (NSAIDs) for treating acute ankle sprains in adults: benefits outweigh adverse events. Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA. 2015 Aug; [PubMed PMID: 24474583]|
|||May JJ,Lovell G,Hopkins WG, Effectiveness of 1% diclofenac gel in the treatment of wrist extensor tenosynovitis in long distance kayakers. Journal of science and medicine in sport. 2007 Feb; [PubMed PMID: 16787761]|
|||Barkin RL, Topical Nonsteroidal Anti-Inflammatory Drugs: The Importance of Drug, Delivery, and Therapeutic Outcome. American journal of therapeutics. 2015 Sep-Oct; [PubMed PMID: 22367354]|
|||Vane JR, Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature: New biology. 1971 Jun 23; [PubMed PMID: 5284360]|
|||Chaiamnuay S,Allison JJ,Curtis JR, Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2006 Oct 1; [PubMed PMID: 16990630]|
|||Scott LJ, Intravenous ibuprofen: in adults for pain and fever. Drugs. 2012 May 28; [PubMed PMID: 22621696]|
|||Sostres C,Gargallo CJ,Arroyo MT,Lanas A, Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best practice [PubMed PMID: 20227026]|
|||Whelton A, Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. The American journal of medicine. 1999 May 31; [PubMed PMID: 10390124]|
|||Harirforoosh S,Asghar W,Jamali F, Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. Journal of pharmacy [PubMed PMID: 24393558]|
|||Sriuttha P,Sirichanchuen B,Permsuwan U, Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials. International journal of hepatology. 2018; [PubMed PMID: 29568654]|
|||Schafer AI, Effects of nonsteroidal anti-inflammatory therapy on platelets. The American journal of medicine. 1999 May 31; [PubMed PMID: 10390125]|
|||Berkes EA, Anaphylactic and anaphylactoid reactions to aspirin and other NSAIDs. Clinical reviews in allergy [PubMed PMID: 12668894]|
|||Szczeklik A, Adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs. Annals of allergy. 1987 Nov; [PubMed PMID: 3318575]|
|||Rothenberg RJ,Holcomb JP Jr, Guidelines for Monitoring of NSAIDS: Who Listened? Journal of clinical rheumatology : practical reports on rheumatic [PubMed PMID: 19078482]|
|||Hunter LJ,Wood DM,Dargan PI, The patterns of toxicity and management of acute nonsteroidal anti-inflammatory drug (NSAID) overdose. Open access emergency medicine : OAEM. 2011; [PubMed PMID: 27147851]|